Renin-angiotensin system inhibition reduces glycine-induced glomerular hyperfiltration in conscious rats
- PMID: 1560388
Renin-angiotensin system inhibition reduces glycine-induced glomerular hyperfiltration in conscious rats
Abstract
It has been reported that high protein intake or amino acid infusion-induced glomerular hyperfiltration are accompanied by an elevation of plasma renin activity and renal renin mRNA. We therefore investigated the effect of inhibition of the renin-angiotensin system by SK&F 108566, a novel, nonpeptide angiotensin II (AII) receptor antagonist, or by enalapril, an angiotensin converting enzyme inhibitor, on glycine-induced hyperfiltration. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and p-aminohippurate clearances in conscious chronically instrumented rats. Glycine infusion (3.7 mg/min i.v.; n = 8) significantly increased GFR by 27% (from 1.09 +/- 0.53 to 1.38 +/- 0.08 ml/min.100 g), ERPF by 22% (2.96 +/- 0.30 to 3.61 +/- 0.32 ml/min.100 g) and significantly decreased effective renal vascular resistance by 22% [from 25.4 +/- 2.9 to 20.8 +/- 2.5 mm Hg/(ml/min.100 g)]. SK&F 108566 (30 micrograms/kg.min) or enalapril (1 mg/kg), at doses which inhibited the pressor effects of AII or AI, respectively, but had no significant influence on base-line GFR and ERPF, significantly attenuated the glycine-induced glomerular hyperfiltration and hyperemia. In the presence of SK&F 108566 or enalapril, glycine resulted in only small, statistically insignificant changes in GFR (from 1.07 +/- 0.03 to 1.10 +/- 0.04 and from 1.19 +/- 0.03 to 1.21 +/- 0.08 ml/min.100 g, respectively), ERPF (from 3.27 +/- 0.21 to 3.53 +/- 0.26 and from 3.57 +/- 0.11 to 3.41 +/- 0.38 ml/min.100 g, respectively) and effective renal vascular resistance [from 21.2 +/- 1.9 to 19.2 +/- 1.6 and from 18.4 +/- 0.9 to 20.2 +/- 2.2 mm Hg/(ml/min.100 g], respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Renal response to pentobarbital anesthesia in rats: effect of interrupting the renin-angiotensin system.J Pharmacol Exp Ther. 1986 Mar;236(3):721-8. J Pharmacol Exp Ther. 1986. PMID: 3512818
-
Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.J Pharmacol Exp Ther. 1992 Jan;260(1):175-81. J Pharmacol Exp Ther. 1992. PMID: 1309870
-
The role of adenosine in glycine-induced glomerular hyperfiltration in rats.J Pharmacol Exp Ther. 1992 Dec;263(3):1188-94. J Pharmacol Exp Ther. 1992. PMID: 1469627
-
Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.J Hypertens Suppl. 1999 Jun;17(2):S27-32. J Hypertens Suppl. 1999. PMID: 10465064 Review.
-
The renal profile of eprosartan.Pharmacotherapy. 1999 Apr;19(4 Pt 2):86S-94S. doi: 10.1592/phco.19.7.86s.30949. Pharmacotherapy. 1999. PMID: 10213527 Review.
Cited by
-
Eprosartan: a review of its use in the management of hypertension.Drugs. 2000 Jul;60(1):177-201. doi: 10.2165/00003495-200060010-00009. Drugs. 2000. PMID: 10929934 Review.
-
Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy.Physiol Rep. 2021 Jan;9(1):e14697. doi: 10.14814/phy2.14697. Physiol Rep. 2021. PMID: 33427414 Free PMC article.